Koncare Biotech, under the leadership of CEO and founder Concha Pérez, has firmly established itself as a pioneering force in the treatment of digestive disorders. The forward-thinking company is making significant strides in the rapidly evolving nutraceutical industry, leveraging clinical research, a deep understanding of gut health, and cutting-edge science to provide effective solutions. Specializing in digestive pathologies, Koncare’s holistic and integrative approach addresses the root causes of common ailments such as irritable bowel syndrome (IBS), intestinal dysbiosis, and metabolic-associated fatty liver disease (MAFLD), setting it apart from other players in the market. What makes Koncare truly unique, according to Pérez, is the company’s ability to blend applied clinical research with an integrative vision of health. It stands out by developing products with a solid scientific foundation that are also highly personalized for each digestive condition. This evidence-based, individualized approach enables Koncare to tackle complex, multifactorial digestive issues in a way that aligns with the latest scientific trends, anticipating developments in neurogastroenterology and gut microbiota. “We incorporated principles of neurogastroenterology and gut microbiota long before they became mainstream,” Concha Pérez notes, underscoring the company’s commitment to staying ahead of the curve. Its ability to foresee industry shifts is one reason Koncare recently expanded internationally, securing a distribution agreement in the UAE with Dr. Safwan Nached, CEO of Pharmapal—further solidifying its global presence. Koncare’s product portfolio reflects its philosophy of clinical innovation. Among the standout offerings is Disibex Forte, a specialized formulation designed to treat functional dyspepsia. This product goes beyond symptomatic relief by targeting the underlying pathophysiological mechanisms. Disibex Forte’s unique combination of probiotic strains, plant extracts, digestive enzymes, and immune modulators makes it one of a kind in its category. It also plays a crucial role as an adjuvant in Helicobacter pylori eradication therapy and in preventing and treating travelers’ diarrhea..

Diagnosing Multiple Sclerosis (MS) has traditionally involved a slow, invasive, and uncertain process— one that leaves patients waiting and clinicians guessing. But ALA Diagnostics is reshaping that path with a groundbreaking innovation: the first clinically validated, blood-based diagnostic test for MS, the MS KIT. “This isn’t just another biomarker—it’s a paradigm shift,” says José Ramón Montero, general manager and founder of ALA Diagnostics. “We’re replacing invasive, costly procedures with a simple serum test that delivers clarity in hours, not months.” A First-of-Its-Kind Diagnostic Breakthrough At the heart of the MS KIT is a proprietary recombinant protein biomarker clinically validated in hundreds of samples. Paired with ALA’s proprietary algorithm, it achieves over 90% diagnostic accuracy, even in early clinical stages like Clinically Isolated Syndrome (CIS). Unlike other tools designed for monitoring or prognosis, the MS KIT was built specifically for diagnosis. It can distinguish MS not only from healthy individuals but also from other inflammatory neurological conditions that often mimic MS in imaging or clinical presentation. Simpler for Labs, Faster for Patients Clinicians often struggle to make early, confident decisions because traditional diagnostic criteria involve MRI, lumbar punctures, and long observation periods. With the MS KIT, diagnosis becomes objective, fast, and noninvasive. Integration is seamless for labs. The MS KIT follows a classic ELISA format, meaning it fits directly into existing lab workflows—no new infrastructure, no steep learning curve. “We designed the kit to be easy to implement anywhere—from large reference hospitals to regional centers,” explains Montero. “There’s no barrier to adoption.”.